Pipeline
OKYO is focused on the development of OK-101 to treat ocular diseases, including dry eye, uveitis, allergic conjunctivitis and ocular pain. The main focus of the company is clinical development of OK-101 to treat dry eye disease (DED).
A Focus on Ocular Therapies
Pipeline
| Asset | Indication | Pre-Clinical | IND-Enabling Studies | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| OK-101 | Dry Eye | |||||
| Neuropathic Corneal Pain | ||||||
| Allergic Conjunctivitis | ||||||
| Uveitis | OK-201 | Discovery Program | ||||
| Drug | Indication | Stage |
|---|---|---|
| OK-101 | Dry Eye | Phase 2* |
| Neuropathic Corneal Pain | IND-Enabling Studies | |
| Allergic Conjunctivitis | Pre-Clinical | |
| Uveitis | Pre-Clinical | OK-201 | Discovery Program |
OK-101 Development Timeline
- Skipping Phase 1
- Designing Phase 2 effectively as a Phase 3 registration trial
